Sarepta Therapeutics
SRPT
377 hedge funds and large institutions have $8.66B invested in Sarepta Therapeutics in 2022 Q3 according to their latest regulatory filings, with 79 funds opening new positions, 121 increasing their positions, 116 reducing their positions, and 37 closing their positions.
114% more first-time investments, than exits
New positions opened: 79 | Existing positions closed: 37
68% more call options, than puts
Call options by funds: $269M | Put options by funds: $160M
58% more capital inflows, than outflows
Capital inflows: $1.37B | Capital outflows: $863M
14% more funds holding
Funds holding: 332 → 377 (+45)
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
5.57% more ownership
Funds ownership: 83.85% → 89.43% (+5.6%)
4% more repeat investments, than reductions
Existing positions increased: 121 | Existing positions reduced: 116
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Avidity Partners Management
Dallas,
Texas
|
+$95.6M |
| 2 |
OrbiMed
New York
|
+$90.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$89M |
| 4 |
Two Sigma Investments
New York
|
+$76.5M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$74.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$124M |
| 2 |
Janus Henderson Group
London,
|
-$76.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$47.5M |
| 4 |
Farallon Capital Management
San Francisco,
California
|
-$43.4M |
| 5 |
Bellevue Group
Kuesnacht,
Switzerland
|
-$38.7M |
SRPT Hedge Fund Activity: Q3 2022 in Review
377 of the 5,833 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q3 2022, worth a combined $8.66B — up 57% from $5.5B a quarter earlier.
Buyers outnumbered sellers: 79 funds opened new SRPT positions and 37 closed out — a net gain of 42 holders — while 121 added to existing stakes and 116 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $95.6M. The largest seller was Sands Capital Management, cutting an estimated $124M.
- 377 institutional investors held Sarepta Therapeutics (SRPT) as of Q3 2022, up from 332 in Q2 2022.
- Funds reported $8.66B of Sarepta Therapeutics stock for Q3 2022, up 57% quarter-over-quarter.
- 79 funds opened new Sarepta Therapeutics positions in Q3 2022 and 37 closed out, a net change of +42 holders.
- The largest Sarepta Therapeutics buyer in Q3 2022 was Avidity Partners Management, an estimated $95.6M added.
- The largest Sarepta Therapeutics seller in Q3 2022 was Sands Capital Management, an estimated $124M sold.
Based on aggregated 13F filings for Q3 2022.